Drug Approval & Efficacy - Half (50%) of approved cancer drugs lack proof of extending survival for approved uses [1] - The pharmaceutical industry's primary motive is generating profits for shareholders [1] - Financial pressures can lead to rushed clinical trials and approvals based on uncertain evidence [2] Treatment & Dosage - Lower dosages can result in less revenue for pharmaceutical companies [2] - A second line of treatment may not always be beneficial for patients [2] Patient Needs & Conflicts - Clinicians and researchers should focus on patient needs, which can sometimes conflict with other factors [3]